HUTCHMED Receives the Pharmacy and Poisons Board of Hong Kong’s Approval for Elunate (fruquintinib) to Treat Metastatic Colorectal Cancer (CRC)
Shots:
- The approval was granted by the PPBHK following the NMPA approval of Elunate based on the results from the P-III (FRESCO) trial. Fruquintinib (Fruzaqla) was also approved by the US FDA in Nov 2023 for CRC
- The P-III (FRESCO) study evaluated the safety & efficacy of Elunate (n=278) vs PBO (n=138) in patients with metastatic CRC with OS as 1EP & PFS, ORR & DCR as 2EPs. The results from the trial depicted a mOS of 9.3mos. vs 6.6mos. & a mPFS of 3.7mos. vs 1.8mos.
- Following the approval, Elunate will be marketed in Hong Kong by HUTCHMED whereas it has been developed & commercialized in mainland China in collaboration with Eli Lilly & Takeda has the exclusive license for areas outside mainland China, Hong Kong & Macau
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Reports the NDA Submission of Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
